Should you buy Co-Diagnostics stock now?
No, the technical signal for Co-Diagnostics is currently Strong Sell. Co-Diagnostics trades at $1.15 as of Oct 7, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -0.056 with rising momentum (signal: -0.087); RSI is at 49.1 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average). The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Co-Diagnostics stock?
There is currently no active analyst price target for Co-Diagnostics.
Is Co-Diagnostics a dividend stock?
No, Co-Diagnostics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Co-Diagnostics stock?
Co-Diagnostics is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 225.5%, which classifies the stock as Extremely speculative.
Is Co-Diagnostics overvalued?
Co-Diagnostics has the following valuation ratios: a P/S ratio of 10.5, a P/B ratio of 0.6.
Is Co-Diagnostics overbought?
No, Co-Diagnostics is not overbought. RSI is at 49.1 (neutral zone). The technical indicators show: RSI is at 49.1 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 7.0% above the 20-day average (short-term uptrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Co-Diagnostics earnings report?
Co-Diagnostics reports its next earnings on November 12, 2026. The stock currently trades at $1.15.
Is Co-Diagnostics shorted?
Yes, Co-Diagnostics is shorted with 4.4% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Co-Diagnostics stock?
No, insiders are not buying Co-Diagnostics shares – they are net sellers. Across the last 20 reported transactions, the split is 6 purchases and 14 sales, with a net 4,695,929 $ sold. Active sellers include Durenard Eugene, BENSON REED L, Egan Dwight H and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Co-Diagnostics a good stock?
Based on our total score, Co-Diagnostics is rated as a disastrous stock with a total score of 12 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 32/100, Quality: 5/100. In addition: technical signal: Strong Sell. Whether Co-Diagnostics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Co-Diagnostics stock?
The outlook for Co-Diagnostics based on current data: the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on Nov 12, 2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Co-Diagnostics stock rising?
Co-Diagnostics is rising right now. The technical indicators show: the price is 7.0% above the 20-day average; insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Co-Diagnostics go?
There is currently no active analyst price target for Co-Diagnostics. The stock has traded between $0.91 and $46.50 over the last 52 weeks. The price is 97.5% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Co-Diagnostics fall?
The stock has traded as low as $0.91 over the last 52 weeks — that is 20.9% below the current price of $1.15. The biggest decline (drawdown) in the same period was 98.0% from high to low. Within a year, the price typically swings about ±225.5% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Co-Diagnostics do?
Co-Diagnostics, Inc. makes tests that can detect diseases by analyzing DNA and RNA, which are the genetic building blocks found in humans, animals, plants, and germs. The company makes money by developing and selling these tests, known as PCR tests, around the world.
Co-Diagn... The company belongs to the Healthcare sector, more specifically the Medical Devices industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Co-Diagnostics as an investment.
Did Co-Diagnostics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Co-Diagnostics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Co-Diagnostics making money or losing money?
We have no current profitability data for Co-Diagnostics. See the latest report in the earnings history above.
Can Co-Diagnostics go bankrupt?
The bankruptcy risk of Co-Diagnostics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -34.12 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 18% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Co-Diagnostics have a lot of debt?
No, Co-Diagnostics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 18%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
